Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Irritable Bowel Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    114 result(s) found for: Irritable Bowel Syndrome. Displaying page 3 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2010-018300-85 Sponsor Protocol Number: NAK-04 Start Date*: 2010-07-23
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) SE (Completed) IT (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-000895-14 Sponsor Protocol Number: NAK-07 Start Date*: 2014-01-27
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in f...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000894-56 Sponsor Protocol Number: NAK-06 Start Date*: 2014-02-26
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-024177-39 Sponsor Protocol Number: RIBS-MIC/002/2010 Start Date*: 2011-02-01
    Sponsor Name:ALFA WASSERMANN
    Full Title: Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
    Medical condition: Non constipation Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000307-32 Sponsor Protocol Number: Repha_1439 Start Date*: 2020-05-12
    Sponsor Name:Repha GmbH
    Full Title: Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D)
    Medical condition: Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018902-35 Sponsor Protocol Number: TC-6499-12-CLP-004 Start Date*: 2010-05-05
    Sponsor Name:Targacept Inc
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Proof of Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominan...
    Medical condition: Constipation Predominant Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013426-16 Sponsor Protocol Number: 5953 Start Date*: 2009-11-16
    Sponsor Name:University of Southampton
    Full Title: Management of Irritable Bowel Syndrome in Primary Care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy w...
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002741-38 Sponsor Protocol Number: SymPro2012 Start Date*: 2013-10-02
    Sponsor Name:SymbioPharm GmbH
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy,safety and tolerability of oral treatment with non-pathogenic bacterial lysate of E. coli and E. faecalis c...
    Medical condition: Irritable Bowel Syndrome (IBS) with recurrent abdominal pain or discomfort according to ‘S3 Guideline and Rome III criteria’
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016754 10048571 Irritable bowel syndrome aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001203-36 Sponsor Protocol Number: BHT-II-002 Start Date*: 2019-01-09
    Sponsor Name:4D Pharma Plc
    Full Title: A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bow...
    Medical condition: Irritable Bowel Syndrome (IBS), subtypes IBS-C and IBS-D
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    20.1 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000916-25 Sponsor Protocol Number: GIU-5-ASA1.2 MMx-01-03 Start Date*: 2004-09-28
    Sponsor Name:GIULIANI
    Full Title: A PHASE III PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUPS, STUDY, TO ASSESS THE EFFECT OF 5-ASA MMx 1.2 g Tablets IN MAINTENANCE OF REMISSION OF LEFT-SIDED ULCERATIVE COLITIS
    Medical condition: TREATMENT OF ULCERATIVE COLITIS IN ACTIVE PHASE AND IN THE MAINTENANCE OF CLINICAL REMISSION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021972 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002976-14 Sponsor Protocol Number: CRI103143 Start Date*: 2006-09-27
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of ...
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019343-20 Sponsor Protocol Number: 654-002 Start Date*: 2010-10-15
    Sponsor Name:LOTUS PHARMACEUTICAL CO., LTD.
    Full Title: A DOUBLE-BLIND, RANDOMISED, PARALLEL-GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DOSE LEVELS OF OMS210 WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL...
    Medical condition: Diarrhoea predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048571 Irritable bowel syndrome aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) CZ (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024028-24 Sponsor Protocol Number: IBS-PTX Start Date*: 2012-05-30
    Sponsor Name:Hospital Universitario de Canarias
    Full Title: EFFECT OF PENTOXIFYLLINE ON THE TIGHT JUNCTIONS (TJs) OF THE INTESTINAL MUCOSA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS).
    Medical condition: IRRITABLE BOWEL SYNDROME (IBS) generates tomach pain and changes in depositions number and consistency. IBS has a high prevalence in Digestive consultations. In spite of this, we haven´t good treat...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003942-28 Sponsor Protocol Number: MLN0002-3023 Start Date*: 2016-05-29
    Sponsor Name:Takeda Development Centre Europe, Ltd.
    Full Title: Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying...
    Medical condition: Primary Sclerosing Cholangitis (PSC) Inflammatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004871 10036732 Primary sclerosing cholangitis LLT
    19.0 10017947 - Gastrointestinal disorders 10021972 Inflammatory bowel disease PT
    19.0 10017947 - Gastrointestinal disorders 10021973 Inflammatory bowel disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Prematurely Ended) GB (Completed) HU (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003976-38 Sponsor Protocol Number: IBO Start Date*: 2020-04-23
    Sponsor Name:Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)
    Full Title: EFFECT OF STW5 (Iberogast ®) AND STW5-II (Iberogast N®) ON TRANSIT AND TOLERANCE OF INTESTINAL GAS
    Medical condition: Irritable bowel syndrome and functional dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10064536 Functional dyspepsia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000818-29 Sponsor Protocol Number: MCP-103-403 Start Date*: 2016-08-08
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrom...
    Medical condition: Irritable Bowel Syndrome with Constipation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002116-10 Sponsor Protocol Number: i3.1_IBS+SIBO Start Date*: 2019-09-27
    Sponsor Name:AB-Biotics S.A.
    Full Title: Interventional post-marketing study to evaluate i3.1 efficacy on SIBO (Small Intestinal Bacterial Overgrowth)reduction in IBS (Irritable bowel syndrom) patients
    Medical condition: Irritable Bowel Syndrome (IBS) + Small Intestinal Bacterial Overgrowth (SIBO)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005414-20 Sponsor Protocol Number: 14/05 Start Date*: 2006-03-06
    Sponsor Name:ISTITUTO PER L INFANZIA BURLO GAROFOLO
    Full Title: Randomized controlled double-blind Vs. placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn s disease and ulcerative colitis.
    Medical condition: Inflammatory Bowel Disease Crohn Disease, Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021972 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004162-13 Sponsor Protocol Number: SAE-13/IBD Start Date*: 2007-02-27
    Sponsor Name:Charité Universitätsmedizin, Campus Charité Mitte
    Full Title: Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease
    Medical condition: Active inflammatory bowel disease, i.e. either left-sided ulcerative colitis or Crohn´s Disease (Colon) with signs of inflammation within 40 cm ab ano.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021972 Inflammatory bowel disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:13:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA